Form 4: BioCryst Pharmaceuticals Director Steven Galson Reports New Equity Grants and Trust Transfers

BioCryst Pharmaceuticals, Inc. Director Steven Galson reported the acquisition of 12,500 Restricted Stock Units and 27,181 stock options, alongside previous transfers of 23,940 shares to a living trust.

Summary

• Steven Galson, a Director at BioCryst Pharmaceuticals, Inc. (BCRX), reported transactions on June 12, 2025.
• He acquired 12,500 shares of Common Stock as Restricted Stock Units (RSUs) at a price of $0, which are set to vest on the first anniversary of the grant date.
• He also received an automatic grant of 27,181 stock options with an exercise price of $10.4, which will be exercisable from June 12, 2026, and expire on June 12, 2035.
• These grants were made pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.
• Following these transactions, Galson's direct beneficial ownership of Common Stock is 24,991 shares.
• He indirectly beneficially owns 45,880 shares of Common Stock through a living trust.
• Previous transfers to the trust include 12,600 shares on July 16, 2024, and 11,340 shares on October 2, 2024, both for no consideration.

Sentiment

Score: 6

Explanation: The document is largely neutral as it reports routine insider transactions and compensation. The grants of RSUs and options are a positive for aligning director interests with shareholders, but the trust transfers are a personal matter.

Positives

• Director Steven Galson received new equity grants (12,500 RSUs and 27,181 stock options), which aligns his interests with those of shareholders by tying his compensation to the company's stock performance.
• The grants are part of a formal BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, indicating a structured and transparent approach to director remuneration.

Negatives

• The transfers of 23,940 shares to a living trust, while common for estate planning, represent a change in direct ownership for the reporting person, though indirect beneficial ownership is retained.

Risks

• No specific risks related to company operations, financial health, or future performance are mentioned in this filing, as it is primarily an insider transaction report.

Future Outlook

The document indicates future vesting of 12,500 Restricted Stock Units on June 12, 2026, and the exercisability of 27,181 stock options from the same date until their expiration on June 12, 2035, aligning director incentives with long-term company performance.

Management Comments

• "The undersigned hereby constitutes and appoints each of Alane P. Barnes and Sara A. Mykrantz, signing singly and not jointly, with full power of substitution, as the undersigneds true and lawful attorney-in-fact to prepare, execute, and submit Section 16 Filings to the SEC." (From Power of Attorney, signed by Steven Galson)
• "The undersigned acknowledges that such attorneys-in-fact, in serving in such capacity at the request of the undersigned, do not assume any of the undersigned's responsibilities to comply with the Exchange Act or any rule or regulation of the SEC." (From Power of Attorney, signed by Steven Galson)

Industry Context

This filing is a routine insider transaction report common in the biotechnology and pharmaceutical industry, reflecting standard compensation practices for non-employee directors. It does not provide specific insights into broader industry trends but highlights how companies like BioCryst Pharmaceuticals incentivize their leadership through equity awards.

Management Changes

Corporate Governance

Related Party Transactions

• Steven Galson transferred 12,600 shares on July 16, 2024, and 11,340 shares on October 2, 2024, to a living trust for no consideration. The reporting person remains an indirect beneficial owner of these shares.

Stakeholder Impact

• Shareholders: The equity grants to Director Steven Galson align his interests with those of shareholders, as his compensation is tied to the company's stock performance. The disclosure provides transparency regarding insider ownership and transactions.

Next Steps

• Vesting of 12,500 Restricted Stock Units on June 12, 2026.
• Stock options becoming exercisable on June 12, 2026.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Beneficial Ownership, Steven Galson